XML 15 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
ASSETS    
Cash and cash equivalents $ 21,805 $ 22,593
Marketable securities 21,544 27,942
Prepaid and other current assets 4,210 3,389
Total current assets 47,559 53,924
Property and equipment, net 146 175
Acquired license - intangible, net 245 263
Other assets 290 332
Total assets 48,240 54,694
Liabilities    
Accounts payable 1,263 2,421
Accrued liabilities 4,070 4,169
Total current liabilities 5,333 6,590
Other long-term liabilities 164 210
Total liabilities 5,497 6,800
Commitments and Contingencies (Note 13)
Stockholders' Equity    
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,308,171 and 8,150,635 shares at March 31, 2024 and December 31, 2023, respectively; and outstanding, 8,307,433 and 8,149,897 shares at March 31, 2024 and December 31, 2023, respectively 8 8
Additional paid-in capital 577,283 576,971
Treasury stock, at cost; 738 shares at March 31, 2024 and December 31, 2023 (708) (708)
Accumulated deficit (533,482) (528,081)
Accumulated other comprehensive loss (104) (42)
Total Lisata Therapeutics, Inc. stockholders' equity 42,997 48,148
Non-controlling interests (254) (254)
Total equity 42,743 47,894
Total liabilities, non-controlling interests and stockholders' equity $ 48,240 $ 54,694